Relevant bibliographies by topics / Liquide biopsy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Liquide biopsy'

Author: Grafiati
Published: 9 September 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Liquide biopsy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Liquide biopsy"

1

Singh, Pratibha, Meenakshi Gothwal, and Garima Yadav. "Liquid Biopsy in Ovarian Cancer." Indian Journal of Obstetrics and Gynecology 6, no. 4 (2018): 427–31. http://dx.doi.org/10.21088/ijog.2321.1636.6418.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Russo, Antonio, and Antonio Galvano. "Biopsia Líquida en Oncología: ¿Mito o Realidad?" Revista de la Facultad de Medicina Humana 20, no. 1 (January 15, 2020): 8–9. http://dx.doi.org/10.25176/rfmh.v20i1.2643.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Khurshid, Zohaib, and Shahjahan Katpar. "Human Saliva as a Liquid Biopsy for Detecting the SARS-CoV-2." Journal of the Pakistan Dental Association 29, Special Supplement (July 24, 2020): S1—S3. http://dx.doi.org/10.25301/jpda.29s.s1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lavine, M. S. "Liquid Biopsy." Science 328, no. 5975 (April 8, 2010): 141. http://dx.doi.org/10.1126/science.328.5975.141-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gingras, Isabelle, Roberto Salgado, and Michail Ignatiadis. "Liquid biopsy." Current Opinion in Oncology 27, no. 6 (November 2015): 560–67. http://dx.doi.org/10.1097/cco.0000000000000223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Siddiqua, Umme Iffat. "Liquid Biopsy." KYAMC Journal 10, no. 1 (May 22, 2019): 1. http://dx.doi.org/10.3329/kyamcj.v10i1.41473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goodwin, Peter M. "Liquid Biopsy." Oncology Times 38, no. 13 (July 2016): 40. http://dx.doi.org/10.1097/01.cot.0000489521.34002.61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fulmer, Tim. "Liquid biopsy." Science-Business eXchange 5, no. 26 (June 2012): 668. http://dx.doi.org/10.1038/scibx.2012.668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hekmat, K., and C. Bruns. "„Liquid biopsy“." Der Chirurg 90, S2 (February 13, 2019): 120. http://dx.doi.org/10.1007/s00104-019-0845-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hekmat, K., and C. Bruns. "„Liquid biopsy“." Der Chirurg 88, no. 7 (June 14, 2017): 621. http://dx.doi.org/10.1007/s00104-017-0458-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Liquide biopsy"

1

Abbou, Samuel. "Liquid Biopsy in Pediatric Sarcoma." Thesis, université Paris-Saclay, 2022. http://www.theses.fr/2022UPASL037.

Full text
Abstract:
Résumé : Les biopsies liquides ouvrent de nouveaux champs d'applications dans la prise en charge des patients au diagnostic, au cours de leur suivi et également en recherche translationnelle. Ces dernières années, de nombreux efforts ont été consacrés au développement de l'ADN tumoral circulant (ADNct) et des cellules tumorales circulantes (CTC). Il y a malgré tout de nombreux terrains encore en friches dans les cancers de l'enfant, et parmi eux dans les sarcomes pédiatriques.Nous avons souhaité explorer dans ce travail différents aspects des applications cliniques éventuelles et d'utilisation de ces technologies pour la compréhension de la biologie des tumeurs. La première partie de ce projet est une revue de la littérature qui se rapporte à l'application de l'ADNct dans les cancers solides pédiatriques. Nous présentons ensuite un travail de recherche qui vise à utiliser les CTC à visée diagnostique dans les sarcomes à translocation. Cette étude présente une approche permettant d'identifier des fusions pathognomoniques de sarcome à partir de très faibles quantités de tissu fixé, de CTC sur des modèles murins ou chez des patients. La deuxième étude présentée s'intéresse à la détection de l'ADNct au diagnostic de rhabdomyosarcome en utilisant les altérations de nombre de copie de chromosome, les réarrangements chromosomiques et les variants de nucléotide. Nous avons démontré que la détection au diagnostic est faisable et a un impact pronostique fort sur le devenir des patients. La dernière partie de ce manuscrit présente le développement d'un processus de traitement d'échantillons de patient pour détecter et isoler des cellules tumorales circulantes dans le but d'analyser les particularités génomiques de cette population à une résolution cellulaire.Ce travail explore certains aspects de l'utilisation de la biopsie liquide dans les sarcomes pédiatriques, parmi de nombreux autres. Il est crucial dans le développement de ce champ de recherche, de maîtriser les particularités intrinsèques de chaque type tumoral et des technologies disponibles. Nous avons démontré l'utilité d'une telle approche au diagnostic dans deux applications. Cette aire de recherche ouvre de nombreuses possibilités qui appellent à poursuivre les efforts afin d'élargir les applications en recherche et en clinique
Abstract: Liquid biopsy is an opportunity for improved diagnosis, treatment monitoring and genomic studies in oncology. Substantial effort in recent years has focused on circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). However, pediatric cancer, including sarcomas, are still largely unexplored disease areas in this field.In this work, we sought to explore several aspects of liquid biopsy applied to pediatric sarcomas including their clinical use at diagnosis and as a tool to understand tumor biology. We first present a review of the literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies. Then, we report a methodological study using CTC for diagnostic purposes in translocation driven sarcomas. This approach identified fusions from as little as two unstained slides of FFPE tumor biopsy tissue, from CTC collected from tumor-bearing mice, and from liquid biopsy samples from patients with known fusion-positive cancers. The second study focuses on ctDNA for prognostication at the time of diagnosis in rhabdomyosarcoma by detecting copy number alterations, rearrangements, and single-nucleotide variants. Our study demonstrates that baseline ctDNA detection is feasible and has prognostic value. The last part of this work presents the development of a workflow to isolate single sarcoma cancer cells for sequencing, with an ultimate goal to analyze CTC genomic features at a single-cell resolution.This work explores several clinically and scientifically relevant aspects of liquid biopsy in pediatric sarcoma. We showed that liquid biopsy has utility at diagnosis in two different applications. Further development in this field will require a strong knowledge of tumor-specific biology, the clinical care of patients with these diseases, and the adaption of new technologies. My findings demonstrate the transformative possibilities this research may bring to the care of patients with pediatric sarcomas
APA, Harvard, Vancouver, ISO, and other styles
2

Cayron, Helene. "Sélection et capture de biomarqueurs moléculaires et cellulaires à partir d'un fluide complexe." Thesis, Toulouse, INSA, 2016. http://www.theses.fr/2016ISAT0001.

Full text
Abstract:
Ce travail de thèse s'est axé autour de deux approches technologiques issues du domaine de la microfabrication pour la sélection et la capture de biomarqueurs circulants dans le sang. A l'échelle moléculaire, un module d'assemblage capillaire dirigé a été implémenté dans un automate de tamponnage moléculaire puis validé en utilisant un modèle simple, permettant l'isolement et l'étirement de biomolécules individuelles de manière entièrement contrôlée et automatisée à large échelle. Nous avons ensuite appliqué cette technologie à des biomarqueurs moléculaires d'intérêt tels que les ADN libres contenus dans du sang complet, démontrant la capacité de la technique à isoler des acides nucléiques dans un fluide complexe contenant de nombreux éléments cellulaires . A l'échelle cellulaire, une approche innovante pour la sélection et la capture de Cellules Tumorales Circulantes a été développée. Le microdispositif mis au point est fabriqué par écriture laser à 3 dimensions et permet le piégeage physique de ces cellules dans du sang complet non traité tout en les préservant pour une récupération et analyse ultérieure. Après adaptation du microdispositif pour maximiser son efficacité de capture in vitro, une première preuve de concept de capture sélective de cellules cancéreuses dans du sang complet non traité a été réalisée. U n premier prototype pour une utilisation in vivo a été mi s au point et validé in vitro sur la capture de cellules cancéreuses dans du milieu de culture
This research project focused on two technological approaches emerging from microfabrication for the selection and capture of circulating biomarkers from blood. At the molecular scale, this work was based on the automation of a directed capillary assembly protocol. A dedicated module was implemented into an automate for molecular stampin g and validated using a simple molecular model, allowing the elongation and large-scale assembly of single biomolecules in a controlled and automatized manner. The developed technology was then used for the assembly of relevant molecular biomarkers such as cell -free DNA (cf DNA) from untreated whole blood , evidencing the capabilities of this technology to single out nucleic acids from complex fluids composed of other cellular elements. At the cellular scale, an innovative concept for Circulating Tumor Cell s (CTCs) selection and capture was developed . The developed microdevice is fabricated using 30 direct laser writing and allows for a physical capture of cell s from untreated whole blood while preserving them for further recovery and analysis. After having optimized the design in vitro to maximize the capture efficiency of the system, a selective capture of cancer cell s from untreated whole blood was achieved . A first prototype for the in vivo use of this system was also developed and validated in vitro with cancer cells spiked into culture medium
APA, Harvard, Vancouver, ISO, and other styles
3

Jimenez, Zenteno Alejandro Kayum. "Micro-dispositifs pour l'isolement des cellules tumorales circulantes en routine clinique." Thesis, Toulouse 3, 2018. http://www.theses.fr/2018TOU30154.

Full text
Abstract:
Les cellules tumorales circulantes (CTCs) sont la principale voie de dissémination du cancer dans le corps humain au travers de la circulation sanguine. Ces cellules ont la capacité de se détacher de la tumeur primaire, de rejoindre la circulation sanguine et de survivre dans cet environnement. Une sous-population spécifique de ces cellules a la capacité de coloniser de nouveaux tissus et de former des métastases. L'importance de ces cellules rares dans la circulation sanguine a été intensément étudiée au cours des dernières décennies, et il a été constaté que les informations phénotypiques et génomiques qu'elles contiennent pourraient être corrélées avec celles obtenues à partir d'une biopsie tissulaire. De plus, le nombre et l'incidence des CTC chez les patients métastatiques pourraient être utilisés comme indicateurs pronostics. Ainsi, leur isolement à partir d'échantillons sanguins et leur analyse a été proposé en remplacement des biopsies conventionnelles, comme une alternative moins invasive et permettant un échantillonnage plus répété. In fine, la détection et l'analyse des CTC en routine clinique pourraient être utilisées pour le suivi en temps réel des thérapies et de leur efficacité pour améliorer la prise en charge des patients, un pas de plus vers une médecine de précision. Dans ce projet de thèse, nous avons développé de nouveaux micro-dispositifs pour la capture, sous flux, de cellules cancéreuses à partir de sang complet humain. Nous avons exploité les propriétés physiques des CTC, plus grandes et moins déformables que les cellules sanguines normales, pour discriminer ces cellules rares (<1 cellule par mL aux premiers stades de la maladie). Des micro-dispositifs ont été conçus tels des tamis à trois dimensions pour filtrer sélectivement les cellules cancéreuses tout en préservant l'intégrité et la viabilité des cellules. De plus, les dispositifs ont été conçus pour permettre l'accès au matériel biologique isolé et effectuer ainsi une identification des cellules in situ, e.g. par immunocytochimie, mais aussi potentiellement pour servir de plateforme pour une analyse fonctionnelle de ces cellules. Nous avons proposé deux approches totalement compatibles avec la routine clinique. La première consiste en un guide équipé de microdispositifs, conçu pour être introduit directement dans la circulation sanguine au travers d'un cathéter médical et effectuer la capture des cellules cancéreuses in vivo. La deuxième approche vise à réaliser l'isolement des CTCs en utilisant des microdispositifs intégrés à des plateformes ex vivo compatibles avec les consommables médicaux de prélèvement sanguin.[...]
Circulating tumor cells (CTCs) are believed to represent the main pathway of cancer dissemination in the human body through the circulatory system. These cells have the ability to detach from the primary tumor, enter into the bloodstream, and survive in this environment. A specific subpopulation of these cells possesses the capacity of colonizing new tissues and forming metastases. The relevance of these rare cells in the bloodstream has been intensively investigated during the last decades, finding that phenotypic and genomic information they carry could be correlated with that of solid biopsies. Moreover, the number and incidence of CTCs in metastatic patients could be used as an indicator for prognosis. Thus, their isolation from blood samples and analysis has been proposed as a surrogate to solid biopsies, having the added value of being a less invasive procedure and allow a more repeated measure. In fine, the routine analysis of CTCs in clinical practice could be used for the real-time monitoring of therapies and the adaptation of treatment in order to improve the outcome of patients, a step forward towards so-called precision medicine. In this PhD project, we have developed novel micro- devices for the capture, in flow conditions, of tumor-derived cells from human whole blood. CTCs being larger and less deformable than normal blood cells, we exploited theses physical traits to discriminate them. Sieve-like micro-devices were engineered to selectively sort out tumor-derived cells having as a priority the preservation of cell integrity and viability. In addition, devices were designed to allow direct access to the isolated biological material and thus perform in situ cell identification, such as immunocytochemistry, but also to potentially serve as a platform for functional analysis. We proposed two approaches compatible with clinical routine. The first approach consists in a customized guiding-strip equipped with integrated microfilters, designed to be introduced directly within the bloodstream through a conventional medical catheter to perform the capture of tumor-derived cells in vivo. The second approach aims to perform CTC isolation ex vivo through the integration of microfilters into a platform compatible with blood collection medical sets. [...]
APA, Harvard, Vancouver, ISO, and other styles
4

Heeke, Simon. "Développement et implémentation de nouveaux biomarqueurs prédictifs dans le cancer du poumon non à petites cellules - du tissu à la biopsie liquide." Electronic Thesis or Diss., Université Côte d'Azur (ComUE), 2019. http://www.theses.fr/2019AZUR6015.

Full text
Abstract:
Le cancer du poumon est la principale cause de décès liés au cancer dans le monde, tant chez les hommes que chez les femmes. Cependant, le traitement du cancer du poumon a radicalement changé au cours de ces dernières années avec la mise en place de chimiothérapies plus efficaces, mais surtout le développement de traitements ciblés qui permettent une approche thérapeutique personnalisée et avec l'introduction de l'immunothérapie qui a considérablement prolongé la survie de certains patients atteints d’un cancer du poumon non à petites cellules (CPNPC). Bien que ces nouvelles approches thérapeutiques aient permis d'obtenir des réponses parfois spectaculaires, un nombre assez important de patients sont réfractaires à ces traitements. Dans ce contexte, le développement de nouveaux biomarqueurs permettant de sélectionner le meilleur traitement pour le bon patient et au bon moment est crucial pour améliorer les résultats cliniques des patients atteints de CPNPC. Tous les biomarqueurs actuellement à l’étude ne sont pas en mesure d'améliorer cette prédiction, en particulier, la mise en place de certains biomarqueurs en routine clinique est souvent difficile, alors que les résultats préliminaires obtenus in vitro ou même dans les essais cliniques initiaux étaient prometteurs. L'objectif de la thèse a été d’évaluer et d’implémenter de nouveaux biomarqueurs prédictifs de la réponse à l’immunothérapie et aux thérapies ciblées pour la sélection thérapeutique des patients atteints de CPNPC. Dans la première partie de la thèse, est abordé l’importance des biobanques et de la maitrise des ressources biologiques comme pierre angulaire du développement de ces nouveaux biomarqueurs. Nous avons mis en place un mode de fonctionnement qui permet d'entreposer en toute sécurité des collections biologiques d'intérêt et de les utiliser pour les études de recherche de biomarqueurs. Nous décrivons comment une biobanque dédiée à une seule pathologie peut être instaurée et utilisée à des fins de recherche.Au cours de cette thèse est abordée l'évaluation génomique de l'ADN libre plasmatique (cell-free DNA : cfDNA) pour la détection des mutations spécifiques du récepteur du facteur de croissance épidermique (Epidermal growth Factor Receptor : EGFR) est étudiée et évaluée. Nous avons analysé rétrospectivement 324 patients sur une période de trois ans à partir de trois tests biologiques utilisés en routine clinique et nous avons pu démontrer que ces tests sont très « robustes » mais doivent être étroitement contrôlés afin d’éviter de faux résultats positifs ou négatifs. Nous avons ensuite évalué le séquençage à haut débit de l’ADN plasmatique chez ces patients à l'aide d'un test interne développé au laboratoire et d'un test externe et nous avons pu démontrer que ces deux tests étaient fiables pour la détection des altérations génomiques du plasma en routine clinique. Dans la dernière partie de la thèse, je décris comment l'évaluation de grands panels de séquençage ciblés capables d'évaluer la charge tumorale mutationnelle peut être utilisée pour sélectionner les patients pouvant bénéficier d’une immunothérapie anti-tumorale et quels pièges doivent être évités afin d’utiliser ce biomarqueur en routine clinique.En résumé, cette thèse montre la place croissante des nouveaux biomarqueurs permettant la stratification des patients atteints CPNPC pour adapter rapidement leur traitement et décrit les différentes étapes de l’implémentation de ces biomarqueurs tissulaires et circulants dans les soins cliniques courants
Lung cancer is the leading cause of cancer-related deaths worldwide for both men and women. However, the treatment of lung cancer has changed radically in recent years with the introduction of more effective chemotherapies, but above all the development of targeted treatments that allow a personalized therapeutic approach and the introduction of immunotherapy that has considerably prolonged the survival of some patients with non-small cell lung cancer (NSCLC). Although these new therapeutic approaches have made it possible to obtain sometimes spectacular responses, a fairly large number of patients are resistant to these treatments. In this context, the development of new biomarkers to select the best treatment for the right patient at the right time is crucial to improving clinical outcomes for NSCLC patients. Nevertheless, not all biomarkers currently under study are able to improve this prediction, in particular, the implementation of some biomarkers in clinical routine is often difficult, whereas preliminary results obtained in vitro or even in initial clinical trials were promising.The objective of the thesis was to evaluate and implement new biomarkers that predict the response to immunotherapy and targeted therapies for the therapeutic selection of NSCLC patients. The first part of the thesis discusses the importance of biobanks and the control of biological resources as a cornerstone for the development of these new biomarkers. We have implemented an operating procedure that allows us to safely store biological collections of interest and use them for biomarker research studies. We describe how a biobank dedicated to a single pathology can be established and used for research purposes.Additionally, the genomic evaluation of cell-free DNA (cfDNA) for the detection of specific mutations of the Epidermal growth Factor Receptor receptor (EGFR) is studied and evaluated. We retrospectively analyzed 324 patients over a three-year period from three biological tests used in routine clinical practice and were able to demonstrate that these tests are very robust but must be closely controlled to avoid false positive or negative results. We then evaluated the next-generation sequencing (NGS) of plasma DNA using an internal test developed in the laboratory and an external test and were able to demonstrate that both tests were reliable for the detection of genomic alterations in plasma in clinical routine. In the last part of the thesis, I describe how the evaluation of large targeted sequencing panels capable of assessing mutation tumor load can be used to select patients for anti-tumor immunotherapy and what pitfalls should be avoided in order to use this biomarker in clinical routine.In summary, this thesis demonstrates the importance of novel biomarkers for the stratification ofpatients undergoing therapy in NSCLC and contributed to the implementation of tissue and liquidbiopsy-based biomarkers in routine clinical care
APA, Harvard, Vancouver, ISO, and other styles
5

Silva, Luciana Sanches. "Pesquisa de células tumorais circulantes em pacientes com câncer de próstata por método de filtração celular." Botucatu, 2018. http://hdl.handle.net/11449/155896.

Full text
Abstract:
Orientador: Adriana Polachini Valle
Resumo: Introdução: O câncer de próstata (CP) é o mais incidente entre os homens em todas as regiões do Brasil. A detecção e caracterização de células tumorais circulantes (CTCs) tem sido apontada como uma alternativa para melhor compreensão da biologia dos tumores, incluindo câncer de próstata. Objetivo: Este estudo tem como objetivo avaliar a detecção de CTCs em pacientes com tumor de próstata localizado e metastático por teste rápido de filtração celular. Metodologia: Foram incluídos pacientes com diagnóstico anatomopatológico de câncer de próstata ou neoplasia intraepitelial prostática. Os dados demográficos, laudos anatomopatológicos e de Cintilografia Óssea e valores do antígeno prostático especifico ( PSA) foram obtidos pelo estudo dos prontuários médicos dos pacientes. Os pacientes foram classificados como portadores de tumor metastático quando apresentavam evidência de imagem metastática pela Cintilografia Óssea. As CTS foram isoladas por teste rápido de filtração celular com posterior imunocitoquímica utilizando-se anticorpos monoclonais anti-PSA para caracterização câncer de próstata específica das células. Resultados: As CTCs foram detectadas em 9 dos 21 pacientes (43%) com positividade de 60% no grupo metastático e 36% no grupo de tumor localizado. Não foram observadas associações entre os valores de PSA e tratamento instituído com a detecção de CTCS. Discussão: A positividade das CTCs no presente estudo mostrou-se semelhante aos dados da literatura, embora possam ser ci... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Introduction: Prostate cancer (PC) is the most frequent among men in all regions of Brazil. The detection and characterization of circulating tumor cells (CTCs) has been pointed out as an alternative for a better understanding of the biology of tumors, including prostate cancer. Objective: This study aims to evaluate the detection of CTCs in patients with localized and metastatic prostate tumor by rapid cell filtration test. Methodology: Patients with anatomopathological diagnosis of prostate cancer or prostatic intraepithelial neoplasia were included. Demographic data, anatomopathological and bone scintigraphy reports and prostate specific antigen (PSA) values were obtained by the study of patients' medical records. Patients were classified as having metastatic tumor when they presented evidence of metastatic image by Bone Scintigraphy. The CTS were isolated by rapid cell filtration test with subsequent immunocytochemistry using anti-PSA monoclonal antibodies for cell-specific prostate cancer characterization. Results: CTCs were detected in 9 of the 21 patients (43%) with 60% positivity in the metastatic group and 36% in the localized tumor group. No associations were observed between PSA values and treatment established with CTCS detection. Discussion: The positivity of the CTCs in the present study was similar to the data in the literature, although some limitations of the study may be cited, such as a small number of patients included, difficulties encountered by research... (Complete abstract click electronic access below)
Mestre
APA, Harvard, Vancouver, ISO, and other styles
6

Buscail, Etienne. "Intérêt diagnostique de la biopsie liquide dans la prise en charge de l'adénocarcinome canalaire du pancréas à un stade précoce." Thesis, Bordeaux, 2019. http://www.theses.fr/2019BORD0081.

Full text
Abstract:
Introduction:Un des problèmes du cancer du Pancréas (CP) est le temps de latence entre la suspicion du CP et la mise en place des traitements. Les méthodes de biopsie liquide pourraient accélérer la mise en évidence d’éléments tumoraux et le diagnostic.Objectif :L’objectif principal de l’étude était de comparer la performance diagnostique de plusieurs techniques de biopsie liquide chez des patients atteint d’un CP résécable d’emblé. L’objectif secondaire était la corrélation avec le taux de récidive post-opératoire.Méthodes:Tout d'abord, nous avons testé 2 méthodes d'enrichissement CTC pour estimer la sensibilité de la détection CTC avec des expériences de cell-spiking de deux lignées de cellules tumorales pancréatiques dans des échantillons de sang de 24 volontaires sains en utilisant la méthode en gradient de densité OncoQuick® et la méthode de sélection négative RosetteSep™. De plus, les mutations KRAS ont été quantifiées dans l'ADN génomique de cellules purifiées par digital droplet PCR (dd-PCR) avec des amorces spécifiques des allèles.Nous avons conçu un essai clinique prospectif (NCT03032913) visant à détecter les cellules tumorales circulantes (CTC), l’ADN tumoral circulant (ADNct) et les onco-exosomes chez les patients atteint de CP et chez les patients d’un groupe témoin. Pour les CTCs : enrichissement et détection de CTCs par la méthode CellSearch©, méthode d’enrichissement de CTCs RosetteSep® et OncoQuick® puis quantification de l’ADN tumoral par dd-PCR. Les exosomes ont été isolés puis caractérisés avec le taux d’expression de Glypican-1. Tous les patients de l’étude ont eu un prélèvement de sang périphérique, les patients du groupe CP ont eu un prélèvement de sang portal peropératoire.Résultats:La sensibilité analytique était de 100 % pour OncoQuick®, quelle que soit la lignée cellulaire, et se situait entre 70 et 100 % pour RosetteSep™. Le taux moyen de récupération des cellules était de 56±23% pour OncoQuick® contre 39±27% pour RosetteSep™ (p<0,001). Les cellules tumorales de la population de cellules sanguines enrichies ont été détectées par dd-PCR après enrichissement par RosetteSep™ et OncoQuick® La détection des allèles K-RAS mutants par ddPCR après enrichissement de RosetteSepTM était 3 à 4 fois plus sensible qu'après OncoQuick®. Ainsi, RosetteSep™ est plus fiable en termes d'efficacité de récupération et de détection des mutants KRAS que OncoQuick®.De février à novembre 2017, 22 patients atteints de CP résécable et 28 patients témoins ont été inclus. Tous les patients ont été détectés positifs par au moins une méthode. Les CTCs ont été détectées chez 9 patients avec la méthode cellsearch (70% dans le sang portal exclusif) et 13 avec la méthode Rosettesep (60%). Les onco-exosomes ont été détecté chez 14 patients sur 22. L’ADNct n’a été détecté que chez deux patients métastatiques. La détection combinée des CTCs et des onco-exosomes était significativement corrélée à la survie sans récidive.Conclusion:Cette étude suggère que la biopsie liquide combinée peut être un outil prometteur à fois diagnostique et pronostique dans le CP à un stade précoce
Introduction:One of the problems of pancreatic ductal adenocarcinoma (PC) is the latency time between the suspicion of PC and the initiation of treatments, especially neo-adjuvants that require histological evidence. Liquid biopsy methods could be a companion test for diagnosis.Objective :The main objective of the study was to compare the diagnostic performance of several liquid biopsy techniques in patients with resectable pancreatic without neo-adjuvant therapy cancer. The secondary objective was the correlation between the quantification of liquid biopsy parameters and clinic-pathologic features.Methods:First, we tested 2 CTC enrichment methods to estimate the sensitivity of CTC detection with cell spiking experiments of two pancreatic tumour cell lines in blood samples from 24 healthy volunteers using the onco-specific density gradient OncoQuick® and the negative selection enrichment method RosetteSep™. Additionally, KRAS mutations were quantified in genomic DNA of purified cells by digital droplet Q-PCR (dd-PCR) with allele specific primers.We designed a prospective clinical trial (PANC-CTC# NCT03032913) to detect circulating tumour cells (CTC), circulating tumour DNA (ADNct) and onco-exosomes in patients with pancreatic cancer and in patients in a control group using different methods. For CTCs, it was the enrichment and detection of CTCs by the CellSearch© method (reference method), the RosetteSep® and OncoQuick® CTC enrichment method and the quantification of tumor DNA by dd-PCR. Exosomes were isolated and characterized with the expression rate of Glypican-1. All patients in the study had a peripheral blood sample, patients in the PDAC group had a portal blood sample during surgery.Results:Analytical sensitivity was 100% for OncoQuick®, regardless of the cell line, and ranged between 70 and 100% for RosetteSep™. Mean recovery rate of cells was 56±23% for OncoQuick® versus 39±27% for RosetteSep™ (p<0.001). Molecular detection of mutant K-RAS alleles by ddPCR after RosetteSepTM enrichment was 3- to 4-fold more sensitive than after OncoQuick®. Thus, RosetteSep™ is more reliable in terms of recovery efficiency and KRAS mutant detection than OncoQuick®.From February to November 2017, 22 patients with resectable pancreatic cancer and 28 control patients were included. All patients were positive by at least one method. CTCs were detected in 9 patients with the cellsearch method (70% in the exclusive portal blood) and 13 with the Rosettesep method (59%), Onco-exosomes were detected in 14 out of 22(64%) patients in peripheral and/or portal blood. DNAct was detected in only two metastatic patients. The combined detection of CTCs with cellsearch and onco-exosomes was significantly correlated with progression free survival and overall survival when CTC cluster were found.Conclusion: This study suggests that combined liquid biopsy can be a promising tool for both diagnosis and prognosis in early pancreatic cancer
APA, Harvard, Vancouver, ISO, and other styles
7

Sanz, García Enrique. "Análisis de RAS en plasma en cáncer colorrectal metastásico: impacto de la fracción mutante alélica en pronóstico." Doctoral thesis, Universitat Autònoma de Barcelona, 2018. http://hdl.handle.net/10803/666000.

Full text
Abstract:
Introducción: A pesar de los importantes avances en el tratamiento del cáncer de colon metastásico (mCRC), la supervivencia sigue siendo corta. Existen diversos factores pronósticos y predictivos que se han de tener en cuenta, entre ellos la mutación del oncogén RAS presente en más del 40% de tumores. Esta mutación suele ser determinada en tejido sólido pero dada la imposibilidad en ocasiones de obtener suficiente muestra y la heterogeneidad tumoral, la determinación de dicha mutación en el DNA circulante en sangre (biopsia líquida) puede ser realizada por ejemplo mediante BEAMing (basada en la PCR digital). La hipótesis principal de este estudio es que la determinación cuantitativa de esta mutación (fracción mutante alélica –MAF-) podría ser un factor pronóstico o predictor en mCRC. Material y métodos: Se trata de un estudio retrospectivo que incluye 110 pacientes procedentes de dos centros. Se han recogido las principales variables clínicas, patológicas y de supervivencia de estos pacientes así como la determinación de RAS en tejido sólido por la técnica habitual. La determinación de la MAF en plasma se ha realizado mediante la técnica del BEAMing y se ha establecido la correlación con la mutación en tejido sólido mediante PCR en tiempo real. Se ha analizado el impacto pronóstico en supervivencia global (OS) y libre de progresión (PFS) de la MAF de RAS en una población homogénea tratada de forma similar, así como correlación con distintas variables. Resultados: En el total de la población de estudio, se han detectado 62 pacientes (56.4%) que presentaban en plasma alguna mutación de RAS mediante BEAMing. La concordancia entre la determinación mediante PCR en tejido sólido y el BEAMing en plasma fue del 90% con un índice estimado Kappa de Cohen 0.80 (IC 95% 0.68-0.91). No se han objetivado diferencias estadísticamente significativas en OS entre la población RAS mutada y no mutada en tejido sólido y en plasma. Con el fin de homogeneizar la población para el análisis pronóstico de la MAF de RAS se han seleccionado un total de 42 pacientes que no habían recibido cirugía de lesiones metastásicas. No se ha observado correlación estadísticamente significativa con la mayoría de las variables clínicas analizadas salvo localización de metástasis. El análisis de la MAF de RAS basal previo al tratamiento de primera línea reveló una correlación significativa con OS (HR = 3.514; p = 0.00066), siendo los pacientes con menores niveles de MAF de RAS los que tienen una OS mayor. Asimismo, los pacientes con menores niveles de MAF presentaron una mayor PFS aunque no fue estadísticamente significativa dicha tendencia. En el análisis multivariante en primera línea la MAF fue un factor pronóstico independiente en OS (HR = 2.73; p = 0.006) y PFS (HR = 3.74; p = 0.049). Asimismo, la MAF fue más alta en aquellos pacientes con progresión de enfermedad como mejor respuesta (p= 0.007). Conclusiones: La MAF en plasma de RAS puede ser un factor pronóstico en los pacientes con mCRC RAS mutados pudiendo ayudar al clínico a tomar decisiones sobre el tratamiento de dicha enfermedad. No obstante, dada la naturaleza del estudio, es necesario estudios más amplios y prospectivos que puedan validar el uso de esta técnica en la práctica clínica.
Introduction: Despite recent major advances in metastatic colorrectal cancer (mCRC), survival is still poor. There are different prognostic and predictive factors to be taken into account, among them, RAS mutation which is observed in 40% of all tumors. This mutation is determined in solid biopsy but sometimes, as it is not possible to get enough sample for this determination and due to tumor heterogeneity, this mutational status can be analyzed from circulating DNA in blood (liquid biopsy) using BEAMing for instance (a digital PCR-based technology). The main hypothesis of this study is to analyze whether quantitative determination of this mutation (mutant allele fraction-MAF-) could be a prognostic or predictive factor for RAS mutant mCRC. Material and Methods: This is a retrospective study comprising a total of 110 patients from two different sites. Main clinical, pathological and survival data have been recorded as well as determination of RAS mutational status in solid biopsy using routine techniques. MAF determination in plasma has been determined using BEAMing and correlation with mutational status in solid tissue using real time PCR has been analyzed. Prognosis impact in overall survival (OS) and progression free survival (PFS) of RAS MAF in a homogenous cohort has been analyzed as well its correlation with different variables. Results: In the whole population, RAS mutation in plasma has been detected with BEAMing in a total of 62 patients (56.4%). Concordance between real time PCR in solid biopsy and BEAMing in plasma is 90% with an estimated Cohen Kappa index of 0.80 (95% CI 0.68-0.91). No statistical significant differences in OS have been detected between RAS mutant and wild type in solid and liquid biopsy. In order to make population homogenous regarding prognosis impact of RAS MAF, a total of 42 patients who have not been operated for metastatic disease have been selected. There are not statistical significant correlations with the most part of the clinical variables except for metastases location. RAS MAF prior to first line therapy shows a significant correlation with OS (HR = 3.514; p = 0.00066), as RAS MAF is lower in patients with longer OS. Moreover, patients with lower MAF show a trend to longer PFS that is not statistically significant. In the multi-variant analysis, RAS MAF is an independent prognosis factor for OS (HR = 2.73; p = 0.006) and PFS (HR = 3.74; p = 0.049). Moreover, patients with higher MAF tend to have progressive disease as best response to treatment (p = 0.007). Conclusions: RAS MAF in plasma could be an independent prognosis factor in patients with RAS mutant mCRC and may help clinicians to make decisions about management of this disease. However, due to the characteristics of this study, prospective studies are needed to validate this technique for the use in the daily practice.
APA, Harvard, Vancouver, ISO, and other styles
8

Yap, Soo Ann [Verfasser]. "Extracellular vesicles as cancer liquid biopsy biomarker / Soo Ann Yap." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2021. http://d-nb.info/1234982889/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bracht-Loman, Jillian Wilhelmina Paulina. "Validation of liquid biopsy-based analysis on the NanoString nCounter platform." Doctoral thesis, Universitat Autònoma de Barcelona, 2021. http://hdl.handle.net/10803/672549.

Full text
Abstract:
L'avaluació dels marcadors moleculars en teixit tumoral per predir el pronòstic del càncer i la resposta al tractament, també coneguda com a tractament personalitzat, ha transformat la pràctica clínica per a molts tipus de càncer. Es va descobrir que aquesta teràpia dirigida per genotipar, millora la supervivència del pacient i per tant s'han introduït diverses plataformes tècniques en els laboratoris clínics. No obstant això, no tots els tumors es poden biopsiar i, sovint, les quantitats de teixit són insuficients per a la caracterització del tumor. L'ARN, l'ADN i les proteïnes lliures circulants de biòpsies líquides, es poden extreure dels fluids corporals i poden reemplaçar o complementar les biòpsies de teixit. Les biòpsies líquides tenen diversos avantatges: la possibilitat de realització d’ estudis de serie o mínimament invasiva i permet analitzar l'heterogeneïtat tumoral. Malauradament, encara hi ha una gran bretxa entre la recerca bàsica i la implementació clínica de biòpsies líquides, principalment a causa de la manca de metodologies estandarditzades. A més, les plataformes tècniques que s'utilitzen actualment, no sempre són adequades per analitzar la baixa quantitat i qualitat de material del tumor derivat d'una biòpsia líquida. En conseqüència, la validació i implementació dels assajos de biomarcadors en biòpsies líquides en els laboratoris clínics, requereixen una plataforma tècnica estandarditzada que sigui sensible, ràpida, fàcil d'utilitzar, relativamente econòmica, flexible i amb poca quantitat de mostra. La plataforma nCounter es pot utilitzar per analitzar tota classe de molècules, inclosos ARN, ADN i proteïnes. La hibridació de codis de barres codificats per colors pels objectius d'interès permet una lectura directa dels nivells d'expressió de gens i proteïnes o la detecció de mutacions. El desenvolupament d'assaigs de biomarcadors en teixits, usant el nCounter, va conduir a l'aprovació per la FDA de l'assaig Prosigna™ per a ús clínic en la tipificació del càncer de mama. Els esforços anteriors també han destacat el potencial d'aquesta plataforma per analitzar molècules derivades i amplificades de biòpsies líquides, encara que es necessiten estudis de validació en l'entorn clínic. En aquesta tesi validem l'ús de la plataforma NanoString nCounter per analitzar material de biòpsies líquides i desenvolupar assajos de biomarcadors clínicament rellevants.
La evaluación de los marcadores moleculares en tejido tumoral para el pronóstico del cáncer y la predicción de respuesta al tratamiento (lo que habitualmente se conoce como tratamiento personalizado) ha transformado la práctica clínica a la hora de tratar muchos tipos de cáncer. Son numerosos los trabajos que desde hace tiempo respaldan el efecto que esta terapia dirigida por genotipo tiene sobre los pacientes oncológicos mejorando la supervivencia del paciente; consecuentemente, un amplio rango de plataformas técnicas han sido implementadas en los laboratorios clínicos en los últimos años. Sin embargo, no todos los tumores se pueden biopsiar y, a menudo, las cantidades de tejido son insuficientes para la caracterización del tumor. Las biopsias líquidas, como el ARN, el ADN o las proteínas circulantes tanto libres como encapsuladas en una membrana, pueden extraerse de los fluidos corporales reemplazando o complementando de este modo las tradicionales biopsias de tejido. Las biopsias líquidas tienen varias ventajas: ofrecen la posibilidad de realizar estudios seriados, son mínimamente invasivas y permiten analizar la heterogeneidad tumoral. Desafortunadamente, todavía existe una gran brecha entre la investigación básica y la implementación clínica de las biopsias líquidas, principalmente debido a la falta de metodologías estandarizadas. Además, las plataformas técnicas que se utilizan actualmente no siempre son adecuadas para analizar la baja cantidad y calidad de material del tumor procedente de una biopsia líquida. En consecuencia, la validación e implementación de los ensayos de biomarcadores en biopsias líquidas en los laboratorios clínicos requieren una plataforma técnica estandarizada que sea sensible, rápida, fácil de usar, viable económicamente, flexible y que requiera un aporte inicial de ácidos nucleicos bajo, debido a la baja concentración que normalmente se obtiene en las biopsias líquidas. La plataforma nCounter se puede utilizar para analizar todo tipo de moléculas, incluyendo ARN, ADN y proteínas. La hibridación de diferentes códigos formados por moléculas de colores siguiendo patrones específicos con secuencias de interés permite una lectura directa de los niveles de expresión de genes y proteínas o la detección de mutaciones. El desarrollo de ensayos de biomarcadores en tejidos usando nCounter condujo a la aprobación por la administración de fármacos y alimentos de los Estados Unidos (FDA) del ensayo Prosigna ™ para su uso clínico en la tipificación del cáncer de mama. Numerosos estudios han destacado el potencial de esta plataforma para analizar moléculas derivadas y amplificadas de biopsias líquidas, aunque estudios de validación en el entorno clínico aun son necesarios. El objeto de esta tesis es la validación del uso de la plataforma NanoString nCounter para analizar material de biopsias líquidas y desarrollar ensayos de biomarcadores clínicamente relevantes.
The assessment of predictive- and prognostic molecular markers in tumor tissue, also known as personalised treatment, has transformed clinical practice for many cancer types. This genotype-directed therapy was found to improve patient survival, and several technical platforms have been introduced in clinical laboratories since then. However, not all tumors can be biopsied and tissue quantities are often insufficient for tumor characterisation. Liquid biopsies, such as membrane-encapsulated- or circulating free RNA, DNA and proteins, can be derived from body fluids and can replace or complement tissue biopsies. They have several advantages, such as repeated sampling, a minimally invasive character and heterogeneous profiling. Unfortunately, there is still a big gap between basic research and clinical implementation of liquid biopsies, mainly due to the lack of standardised methodologies. In addition, currently used technical platforms are not always suitable to analyze the low quantity and quality of tumor-derived material that can be found in a liquid biopsy. In consequence, large-scale validation and clinical implementation of liquid biopsy-based biomarker assays requires a sensitive, quick, easy-to-use, relatively cheap, flexible and standardized technical platform with low input requirements. The nCounter platform can be used to analyze all types of molecules, including RNA, DNA and proteins. Binding of color coded barcodes to targets of interest allows for either a direct read-out of gene- or protein expression levels or the detection of mutations. Tissue-based biomarker assay development on nCounter led to the FDA approval of the Prosigna™ assay for clinical use in breast cancer subtyping. Previous efforts have also highlighted the potential of this platform to analyze amplified liquid biopsy-derived molecules, although validation studies in the clinical setting are needed. In this thesis we validated the use of the NanoString nCounter platform to analyze material from liquid biopsies and develop clinically relevant biomarker assays.
Universitat Autònoma de Barcelona. Programa de Doctorat en Bioquímica, Biologia Molecular i Biomedicina
APA, Harvard, Vancouver, ISO, and other styles
10

Rauof, Goran, and Jonas Jägerback. "Utvecklingen av ett produktsystem för bättre och billigare cancerdiagnostik : Framtagning av engångskassett och tillhörande basenhet för isolering av cirkulerande och andra suspenderade tumörceller." Thesis, KTH, Maskinkonstruktion (Inst.), 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-99301.

Full text
Abstract:
Det här examensarbetet består i ett produktutvecklingsprojekt som utfördes i samarbete med Liquid Biopsy AB. Syftet med arbetet var att utveckla ett engångskassettsbaserat produktsystem baserat på företagets patentsökta metod för isolering av cancer celler i suspension, inklusive cirkulerande tumörceller. Liquid Biopsy AB är ett svenskt utvecklingsbolag som baserat på ny och unik teknik, är oberoende av proteinmarkörer, använder cirkulerande tumörceller och andra suspenderade tumörceller för att möjliggöra bättre och billigare cancerdiagnostik. Examensarbetet har fokuserat på utvecklingen av engångskassetten, men parallellt arbete har även utförts med tillhörande basenhet. Ulrich och Eppingers produktutvecklingsprocess har utgjort grunden för den process som följts i arbetet, dock med ökat fokus på testning och utvärdering. För att få en bredare kunskapsbas inleddes arbetet med en marknads- och omvärldsanalys samt informationsinsamling om utmaningar och medicintekniska krav. För att tydligt definiera produktvisionen utfördes även undersökningar med potentiella användarna, om företagets patentsökta metod och befintliga prototyper samt framtida förbättringspotential. Det kassettkoncept som utvecklats bygger på användning av provrör av existerande standard, få tillverkningsprocesser och god användarvänlighet, något som samtliga varit av hög prioritet under arbetet. För att säkerställa att produktens flödessystem fungerar som tänkt utfördes tester under prototypframtagningen. Testningen visade att konceptet fungerar i stort sett som tänkt med avseende på flöden, dock förekom vissa toleransproblem som följd av den valda prototypframtagningsprocessen, och vissa andra viktiga egenskaper återstår att testa. Resultatet av utvecklingsprocessen är en första fysisk prototyp av engångskassetten och en funktionell partiell prototyp av basenheten, motsvarande gränssnittet mot engångkassetten, för att möjliggöra testning av engångskassetten. Slutsatsen av arbetet är att det framtagna produktsystemet har tydliga fördelar gentemot företagets befintliga prototyper: inklusive att en engångskassett framtagits, att denna kan utgöra underlag för en produkt, och att denna bland annat har väsentligt kortare processväg vilken i sin tur borde kunna leda till förkortad processtid. Utförd finansiell analys visar även att framtaget produktsystem kan säljas till konkurrenskraftiga priser och med en betydligt lägre instegskostnad än dagens konkurrerande produkter.
This thesis consists of a product development project conducted in collaboration with Liquid Biopsy AB. The purpose of this work was to develop a disposable cartridge-based product system based on the company’s patent-pending method for isolation of circulating tumor cells and other suspended tumor cells. Liquid Biopsy AB is a Swedish medical technology research company with a unique new rheological technology, that is independent of protein markers, using suspended cancer cells, including circulating tumor cells, allows better and cheaper cancer diagnostics than today. The thesis work has focused on the development of the disposable cassette, but parallel work has also been performed with the associated base unit. Ulrich and Eppingers product development process has made up the basis for the process being followed in the thesis work, with increased focus on testing and evaluation. The work began with a market analysis and information gathering on challenges and medical requirements. Several activities were also carried out in order to clearly define the product vision, including user-surveys, analysis of the company's existing prototypes, as well as potential for future improvements. The developed cartridge concept is based on the use of standard test tubes, few manufacturing processes and user-friendliness which all have been high priorities in this work. The cartridge concept consists essentially of various plastic materials and is adapted for manufacturing by injection molding. To ensure that the product’s flow system was operating as intended, tests were conducted during the prototype phase. Testing showed that the concept design flows largely as intended, yet with some tolerance problems as a result of the selected rapid prototyping process, while other essential properties remain to be tested. The result of the development process is a first physical prototype of the disposable cartridge and a partial functional prototype of the base unit to allow testing with the disposable cartridge. The conclusion of this thesis work is that the developed product system has strong advantages over the company’s existing prototypes, including a first version of a disposable cassette that has potential to form the basis of a mass-producible product, significantly shorter processing route which in turn should allow a reduction of the processing time. Financial analysis also indicates that the designed product systems can be sold at competitive prices and with a significantly lower entry cost than today's rivaling products.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Liquide biopsy"

1

Chinen, Ludmilla Thomé Domingos, ed. Atlas of Liquid Biopsy. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Russo, Antonio, Antonio Giordano, and Christian Rolfo, eds. Liquid Biopsy in Cancer Patients. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55661-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Strumfa, Ilze, and Janis Gardovskis, eds. Liquid Biopsy. IntechOpen, 2019. http://dx.doi.org/10.5772/intechopen.73612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Histopathology and Liquid Biopsy [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.87426.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shimada, Hideaki. Biomarkers in Cancer Therapy: Liquid Biopsy Comes of Age. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Liquid Biopsy in Urogenital Cancers and its Clinical Utility. Elsevier, 2022. http://dx.doi.org/10.1016/c2021-0-00436-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Giordano, Antonio, Antonio Russo, and Christian Rolfo. Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution. Humana, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Giordano, Antonio, Antonio Russo, and Christian Rolfo. Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution. Humana, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ravegnini, Gloria, Ambra A. Grolla, Marzia Del Re, Sabrina Angelini, and Ron H. van Schaik, eds. Liquid Biopsy as a Tool for Precision Oncology: New Challenges to Assess Clinical Response. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88966-202-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Liquide biopsy"

1

Castiglia, Marta, Lorena Incorvaia, Valerio Gristina, Umberto Malapelle, Viviana Bazan, Christian Rolfo, and Antonio Russo. "Liquid Biopsy." In Practical Medical Oncology Textbook, 99–122. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-56051-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rao, Jianyu, Weibo Yu, Teresa Kim, and Thomas Lee. "Liquid Biopsy." In Clinical Molecular Diagnostics, 377–94. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-1037-0_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roberts, Rene, Bilal A. Siddiqui, Sumit K. Subudhi, and Rahul A. Sheth. "Image-Guided Biopsy/Liquid Biopsy." In Image-Guided Interventions in Oncology, 299–318. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-48767-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Torres, Jacqueline Aparecida, and Victor Hugo Fonseca de Jesus. "Circulating Tumor Cells in Gastric Cancer." In Atlas of Liquid Biopsy, 103–26. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Souza e Silva, Virgilio, Angelo Borsarelli Carvalho de Brito, and Daniela Costa. "Circulating Tumor Cells in Colorectal Cancer." In Atlas of Liquid Biopsy, 47–63. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tariki, Milena Shizue. "Circulating Tumor Cells in Prostate Cancer." In Atlas of Liquid Biopsy, 93–102. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

de Oliveira, Thiago Bueno. "Circulating Tumor Cells in Head and Neck Cancer." In Atlas of Liquid Biopsy, 27–45. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Braun, Alexcia Camila, and José Gabriel Rodríguez Tarazona. "Circulating Tumor Cells in Mesenchymal Tumors." In Atlas of Liquid Biopsy, 127–47. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ruano, Anna Paula Carreta, and Fernanda Cristina Sulla Lupinacci. "In Vitro and In Vivo Models of Circulating Tumor Cells." In Atlas of Liquid Biopsy, 185–95. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tarazona, José Gabriel Rodríguez, and Ludmilla Thomé Domingos Chinen. "Circulating Endothelial Cells: Characteristics and Clinical Relevance." In Atlas of Liquid Biopsy, 163–68. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Liquide biopsy"

1

Grinyte, Ruta, Thorsten Lux, Mokhtar Chmeissani, and Marc Masa. "Photonics Platform For Liquid Biopsy." In Bragg Gratings, Photosensitivity and Poling in Glass Waveguides and Materials. Washington, D.C.: OSA, 2018. http://dx.doi.org/10.1364/bgppm.2018.jtu2a.50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kim, Hyunji, Fehmi Civitci, Josiah Wagner, Pavana Anur, Matthew Rames, Xiaolin Nan, Terry Morgan, and Thuy Ngo. "Abstract 2286: Liquid biopsy for early cancer detection." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2286.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kim, Hyunji, Fehmi Civitci, Josiah Wagner, Pavana Anur, Matthew Rames, Xiaolin Nan, Terry Morgan, and Thuy Ngo. "Abstract 2286: Liquid biopsy for early cancer detection." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2286.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Megquier, Kate, Kan Xiong, Heather L. Gardner, Justin Rhoades, Viktor Adalsteinsson, Cheryl A. London, and Elinor K. Karlsson. "Abstract A58: Advancing blood biopsy through the canine comparative model." In Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-a58.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Trudel, Suzanne, and Trevor Pugh. "Abstract IA11: Clinical applications of liquid biopsy in multiple myeloma." In Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-ia11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Netto, George J. "Abstract IA26: Liquid biopsy in precision pathology: Plasma and beyond!" In Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-ia26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mohan, S., V. Foy, HS Leong, M. Carter, L. Priest, C. Faivre-Finn, F. Blackhall, D. Rothwell, C. Dive, and G. Brady. "9 Liquid biopsy in small cell lung cancer (SCLC)." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rahimian, Ali, Kyungjin Hong, Clara Neal, Gabriella Iacovetti, Greg Sommer, and Ulrich Schaff. "Abstract 3103: TorqTMsystem improves liquid biopsy sample shipping stability." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sims-Mourtada, Jennifer, Kimberly M. Arnold, and Adam Marsh. "Abstract 4545: A liquid biopsy for breast cancer diagnosis." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zheng, Siyang, Hongzhang He, Faming Wang, and Yuan Wan. "Abstract B53: Extracellular vesicle-based liquid biopsy via lipid-based nanoprobes." In Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-b53.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Liquide biopsy"

1

Liang, Feixin. Progress in Liquid Biopsy: A possible role of neutrophils. Science Repository, August 2018. http://dx.doi.org/10.31487/j.cor.2018.02.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Xuefeng, Haoyu Wang, and Yu Wang. The diagnostic value of liquid biopsy for cervical cancer: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Yu, Hao Yu Wang, and Xue Feng Chen. Diagnostic value of different components of liquid biopsy in ovarian cancer: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Hao Yu, Yu Wang, and Xue Feng Chen. Diagnostic performance of various liquid biopsy methods in the detection of gastric cancer: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Liquide biopsy' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography